Phase 3Enrolling by invitation
A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A Nephropathy
A Phase 3, Single-Arm, Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy
- Sponsor
- Vertex Pharmaceuticals Incorporated (Industry)
- Enrolment
- 605 planned
- Conditions
- Immunoglobulin A Nephropathy
- Interventions
- Povetacicept
- Ages
- adults, older adults
- Registry
- NCT07807995
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to evaluate the long-term safety, tolerability and efficacy of povetacicept in participants with immunoglobulin A nephropathy (IgAN).
Primary outcomes
- Safety and Tolerability as Assessed by Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
History
Primary completion expected
Last registry update
Started
Registered